Design and Characterization of 1,3-Dihydro-2 H -benzo[ d ]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors.
Bamborough, P., Chung, C.W., Goodwin, N.C., Mitchell, D.J., Neipp, C.E., Phillipou, A., Preston, A., Prinjha, R.K., Soden, P.E., Watson, R.J., Demont, E.H.(2023) ACS Med Chem Lett 14: 1231-1236
- PubMed: 37736196 
- DOI: https://doi.org/10.1021/acsmedchemlett.3c00242
- Primary Citation of Related Structures:  
8PXM, 8PXN - PubMed Abstract: 
The 1,3-dihydro-2 H -benzo[ d ]azepin-2-ones are potent and ligand-efficient pan-BET bromodomain inhibitors. Here we describe the extension of this template to exploit a bivalent mode of action, binding simultaneously to both bromodomains. Initially the linker length and attachment vectors compatible with bivalent binding were explored, leading to the discovery of exceptionally potent bivalent BET inhibitors within druglike rule-of-5 space.
Organizational Affiliation: 
GlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, U.K.